Clin2
NCT06346093Possibly a fitRecruiting

Fecal transplant for advanced stomach cancer

Advanced Gastric Cancer

Treatments studied

Part of Cancer, Digestive system clinical trials.

This trial tests whether a fecal transplant (a stool donation from a healthy person) can help patients with advanced stomach cancer respond better to treatment. If you qualify, you would receive the transplant through a colonoscopy, possibly along with other standard therapies.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
124 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have advanced stomach or esophagus cancer that has spread or cannot be removed by surgery
  • You are willing to provide a tumor sample and have at least one tumor that can be measured on a scan (not in the brain)
  • You are generally active and able to care for yourself (ECOG 0 or 1)
  • You are not currently taking antibiotics or strong immune-suppressing drugs (like high-dose steroids)
  • You do not have HIV, active hepatitis B/C, inflammatory bowel disease, or a history of severe allergic reactions to certain foods or anesthesia

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06405113Recruiting· Phase 2
Fecal transplant, chemo, and immunotherapy for advanced stomach cancer

This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.

Changzhou
NCT06924645Not yet recruiting
Fecal Transplant for Gut Symptoms in Extrapulmonary Neuroendocrine Cancer

This study tests whether fecal microbiota transplantation (FMT) – transferring healthy gut bacteria via capsules – can help prevent or ease digestive side effects (like diarrhea or constipation) caused by cancer treatment for extrapulmonary neuroendocrine neoplasms. If you are experiencing such symptoms, this approach might improve your quality of life during treatment.

Hangzhou, Zhejiang
NCT06931808Enrolling by invitation· Phase 4
Fecal transplant with chemo, radiation, and immunotherapy for advanced colon cancer

This study tests a combination of fecal microbiota transplant, chemotherapy, radiation, and immunotherapy (sintilimab) for people with locally advanced rectal cancer. The goal is to see if this approach improves treatment outcomes.

Ningbo, Zhejiang
NCT07509398Not yet recruiting· Phase 2/Phase 3
Fecal transplant with standard first-line therapy for advanced colorectal cancer

This trial tests whether adding a fecal microbiota transplant (FMT) to standard first-line chemotherapy can help shrink or control advanced colorectal cancer that cannot be surgically removed. FMT is a procedure that introduces healthy donor bacteria into your gut to possibly boost your body's response to treatment.

NCT07319364Recruiting· Phase 1
Fecal transplant study for cancer treatment side effects

This trial tests whether fecal transplants (putting healthy donor bacteria into your gut) can help with side effects like diarrhea, constipation, or nausea caused by cancer treatments. It is for people with advanced gastrointestinal cancer who are about to start their fourth round of chemo or targeted therapy.

Zhejiang, Hangzhou
NCT06393400Recruiting· Phase 1
Stool transplant with chemotherapy for advanced pancreatic cancer

This study tests if giving patients a stool transplant (also called FMT) in capsules along with their first chemotherapy can help treat advanced pancreatic cancer that cannot be removed by surgery.

London, Ontario

Hear when a new Advanced Gastric Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.